Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Am J Gastroenterol. 2022 Nov 1;117(11):1834-1844. doi: 10.14309/ajg.0000000000001968. Epub 2022 Aug 23.
There are limited data on the effect and evolution of risk factors for hepatocellular carcinoma (HCC) in patients with virologically cured hepatitis C virus (HCV) infection.
We conducted a retrospective cohort study of patients with HCV who achieved sustained virological response with direct-acting antivirals from 130 Veterans Administration hospitals during 2014-2018, followed through 2021. Cox proportional hazards models were constructed at 3 landmark times (baseline and 12 and 24 months after sustained virological response) to examine associations between demographic, clinical, and behavioral factors and HCC risk, stratified by cirrhosis status.
Among 92,567 patients (32% cirrhosis), 3,247 cases of HCC were diagnosed during a mean follow-up of 2.5 years. In patients with cirrhosis, male sex (hazard ratios [HR]: 1.89, 1.93, and 1.99), cirrhosis duration ≥5 years (HR: 1.71, 1.79, and 1.34), varices (HR: 1.73, 1.60, and 1.56), baseline albumin (HR: 0.48, 0.47, and 0.49), and change in albumin (HR: 0.82 and 0.90) predicted HCC risk at each landmark time. HCV genotype 3, previous treatment, bilirubin, smoking, and race influenced HCC risk at baseline, but their effects attenuated over time. In patients without cirrhosis, diabetes (HR: 1.54, 1.42, and 1.47) and hypertension (HR: 1.59, 1.65, and 1.74) were associated with HCC risk at all landmark times. Changes in fibrosis-4 scores over time were associated with HCC risk both in patients with and without cirrhosis.
Risk factors for HCC were different in patients with and without cirrhosis and some also evolved during follow-up. These factors can help with risk stratification and HCC surveillance decisions in patients with cured HCV.
在丙型肝炎病毒 (HCV) 感染病毒学治愈的患者中,有关肝细胞癌 (HCC) 风险因素的作用和演变的数据有限。
我们对 2014 年至 2018 年期间在 130 家退伍军人事务部医院接受直接作用抗病毒药物治疗实现持续病毒学应答的 HCV 患者进行了回顾性队列研究,并随访至 2021 年。在基线和持续病毒学应答后 12 个月和 24 个月的 3 个时间点,构建 Cox 比例风险模型,以检查在肝硬化状态分层的情况下,人口统计学、临床和行为因素与 HCC 风险之间的关联。
在 92567 例患者(32%为肝硬化)中,平均随访 2.5 年后诊断出 3247 例 HCC。在肝硬化患者中,男性(风险比 [HR]:1.89、1.93 和 1.99)、肝硬化持续时间≥5 年(HR:1.71、1.79 和 1.34)、静脉曲张(HR:1.73、1.60 和 1.56)、基线白蛋白(HR:0.48、0.47 和 0.49)和白蛋白变化(HR:0.82 和 0.90)在每个时间点均预测 HCC 风险。HCV 基因型 3、既往治疗、胆红素、吸烟和种族在基线时影响 HCC 风险,但随着时间的推移其影响减弱。在无肝硬化的患者中,糖尿病(HR:1.54、1.42 和 1.47)和高血压(HR:1.59、1.65 和 1.74)在所有时间点均与 HCC 风险相关。纤维化-4 评分随时间的变化与肝硬化患者和无肝硬化患者的 HCC 风险均相关。
在肝硬化患者和无肝硬化患者中,HCC 的风险因素不同,一些因素在随访期间也发生了演变。这些因素有助于对治愈 HCV 的患者进行风险分层和 HCC 监测决策。